Oncomine Myeloid Assay (DNA + RNA)

What is Oncomine Myeloid Assay GX V2 test?

It’s an NGS-based panel that simultaneously analyzes DNA mutations and RNA fusion transcripts associated with a range of myeloid disorders—including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPNs), chronic myeloid leukemia (CML), and others.  Agilus offers fastest TAT of 3 days for this panel with unmatched sensitivity and accurate results.

Why consider Oncomine Myeloid Assay GX V2 test?

• The Oncomine Myeloid Assay GX V2 is a rapid, comprehensive next‑generation sequencing (NGS) panel designed to profile key DNA mutations and RNA fusions relevant across major myeloid malignancies (AML, MDS, MPN, CML, CMML, JMML) in a single test.
• Broad content: 17 full genes, 28 hotspot genes (DNA), and 30–35 fusion driver genes (RNA),
• Variant types: Detects SNVs, indels, and gene fusions

Who should get this Oncomine Myeloid Assay GX V2 done?

1. Patients Newly Diagnosed with a Myeloid Malignancy

• Acute Myeloid Leukemia (AML)
• Myelodysplastic Syndromes (MDS)
• Myeloproliferative Neoplasms (MPN)
• Chronic Myeloid Leukemia (CML)
• Mixed Phenotype Acute Leukemia (MPAL)

2. Patients Requiring Risk Stratification

• Especially in AML and MDS, certain gene mutations influence prognosis and treatment intensity.

3. Patients Being Evaluated for Targeted Therapies

• If mutations like FLT3, IDH1/2, JAK2, or ABL1 fusions are found, targeted drugs can be used.

More Information: ONCOMINE MYELOID ASSAY GX V2 - 69 GENES ( DNA+RNA)

The Oncomine Myeloid Assay GX v2 is an automated next‑generation sequencing (NGS) panel run on the Ion Torrent Genexus system that profiles DNA mutations and RNA fusions relevant to myeloid malignancies (AML, MDS, MPN, CML, CMML, JMML) in a single assay.

Other Names – Myeloid NGS Panel, Rapid NGS Panel, Oncomine Myeloid Panel, 3 Day genomics, 3 day oncogenomics, Myeloid profiler next, Myeloid Genexus Panel